Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

24 Jun 2014

Abstract excerpt

BACKGROUND: HER2 targeted therapies including trastuzumab and more recently lapatinib have significantly improved the prognosis for HER2 positive breast cancer patients. However, resistance to these agents is a significant clinical problem. Although several mechanisms have been proposed for resistance to trastuzumab, the mechanisms of lapatinib resistance remain largely unknown. In this study we generated new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Protease and Inhibitor Mechanisms
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24958351
DOI: 10.1186/1476-4598-13-157

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PP2A inhibition overcomes acquired resistance to HER2 targeted therapyPMID 24958351Read ↗

Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cellsSemantic proximity Read ↗

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profilesSemantic proximity Read ↗

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.Semantic proximity Read ↗

Mechanisms of lapatinib resistance in HER2-driven breast cancer.Semantic proximity Read ↗

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Semantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cellsSemantic proximity Read ↗

Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.Semantic proximity Read ↗

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsSemantic proximity Read ↗

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Semantic proximity Read ↗

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.